sub:assertion {
  d:DB05479 v:identifier "DB05479" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB05479" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB05479> ;
    dv:drugbank-id "DB05479" ;
    dv:x-cas <http://bio2rdf.org/cas:> ;
    dv:x-chemspider <http://bio2rdf.org/chemspider:17286474> ;
    dv:x-pubchemcompound <http://bio2rdf.org/pubchem.compound:16129664> ;
    dct:description """CZEN-002 is a novel, non-azole anti-fungal synthetic octapeptide, derived from alpha-Melanocyte-Stimulating Hormone (a-MSH). CZEN-002 modulates inflammatory and immune responses. It has also been shown to kill Candida albicans (C. albicans), a single-celled fungal organism that causes a variety of infections, including vaginitis. This organism can invade tissues and produce fatal infections in individuals with compromised immune systems such as those suffering from HIV/AIDS or undergoing organ or bone transplants. The antimicrobial activity of CZEN-002 is unique in that it does not depend on direct damage to the microbial membrane. It appears that CZEN-002 works on a receptor in yeast that has yet to be identified.

Studies attempting to understand the candidacidal activity of derivatives of alpha-MSH have focused on the alpha-MSH amino acid sequence (6-13), which contains the invariant core sequence His-Phe-Arg-Trp (6-9) that is important for binding to the known melanocortin receptors. A second focus was on the sequence Lys-Pro-Val (11-13) that is known to be important for antimicrobial activity."""@en ;
    dct:identifier "drugbank:DB05479" ;
    dct:title "CZEN 002"@en ;
    a dv:Drug ;
    rdfs:label "CZEN 002 [drugbank:DB05479]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05479> .
}